- Revenue and earnings: Thermo Fisher Scientific posted Q3 2025 revenue of $11.12 billion, a 5% increase from the prior year, with adjusted EPS rising 10% to $5.79.
- Strategic initiatives: The company launched new diagnostic and imaging products, acquired key manufacturing assets, and expanded AI collaboration to accelerate drug development and productivity.
Thermo Fisher Scientific has reported its financial results for the third quarter ended September 27, 2025, posting revenue of $11.12 billion, up 5% compared with the same period last year. Adjusted earnings per share (EPS) grew 10% to $5.79, while GAAP EPS remained in line with the prior-year quarter at $4.27.
The company continued to advance its growth strategy through the launch of innovative products and expansion of its manufacturing capabilities. Notable launches include the FDA-approved Oncomine™ Dx Express Test on the Ion Torrent™ Genexus Dx Integrated Sequencer, supporting precision medicine for non-small cell lung cancer, and the Olink® Target 48 Neurodegeneration panel to accelerate research into Alzheimer’s and Parkinson’s diseases. For structural biology applications, Thermo Fisher introduced the Talos™ 12 transmission electron microscope.
Thermo Fisher also strengthened its operational footprint with strategic acquisitions. These include the Filtration and Separation business from Solventum, which complements its bioproduction capabilities, and Sanofi’s sterile fill-finish site in Ridgefield, New Jersey, expanding U.S. drug product manufacturing capacity. In addition, the company repurchased $1 billion of stock during the quarter.
The firm has further integrated artificial intelligence into its operations through a collaboration with OpenAI. This partnership aims to enhance scientific discovery, accelerate drug development, and increase operational efficiency across Thermo Fisher’s global business.
“Our team did an outstanding job and delivered excellent operational performance in the quarter, reflecting the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company. I’m also very pleased with the progress we made executing our strategy – launching outstanding new products, completing complementary acquisitions, and collaborating with OpenAI to accelerate scientific advancement.”
CEO Marc N. Casper
